Skip to search formSkip to main contentSkip to account menu

AME-133v

National Institutes of Health

Related topics

Related topics

1 relation
ocaratuzumab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Abstract 3784: AME-133v, a humanized, Fc-engineered anti-CD20 monoclonal antibody, demonstrates greater B cell depletion than Rituxanin vitro:
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL Purpose The efficacy of AME-133v in depleting B… 
2011
2011
Sustained Depletion of B-Cells by a Humanized, Fc-Engineered Anti-CD20 Antibody, AME-133v, in Patients with Relapsed Follicular Lymphoma
Abstract 4977 Sustained Depletion of B-Cells by a Humanized, Fc-Engineered Anti-CD20 Antibody, AME-133v, in Patients with… 
2011
2011
Population Pharmacokinetics Study of a New Humanized Anti-CD20 Monoclonal Antibody AME-133v (LY2469298) in Patients with Previously Treated Follicular Lymphoma (FL)
Abstract 4982 Background: AME-133v is a humanized monoclonal antibody that was engineered to have increased affinity to CD20 and… 
2008
2008
Abstract LB-70: Preliminary results of a Phase I study of AME-133v, an Fc-engineered humanized monoclonal antibody, in low-affinity FcγRIIIa patients with previously-treated follicular lymphoma
Background: Single-agent rituximab therapy in patients with follicular lymphoma (FL) who have a low-affinity FcγRIIIa (158-FF or… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)